XENON PHARMACEUTICALS INC. Marketable Securities (Current)
XENON PHARMACEUTICALS INC. (XENE) had Marketable Securities (Current) of $811.16 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $811.16M.
- 2026-03-31: Marketable Securities, Current $548.88M.
- 2025-12-31: Marketable Securities, Current $349.72M.
- 2025-09-30: Marketable Securities, Current $357.75M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $811.16M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $548.88M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $349.72M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $357.75M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $352.16M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $432.97M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $484.19M 10-K · filed 2026-02-26 |
| 2024-09-30 | $566.39M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $584.80M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $640.71M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $489.44M 10-K · filed 2025-02-27 |
| 2023-09-30 | $427.10M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $475.05M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $457.53M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $534.85M 10-K · filed 2024-02-29 |
| 2022-09-30 | $534.70M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $418.25M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $421.40M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $376.09M 10-K · filed 2023-03-01 |
| 2021-09-30 | $161.82M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $177.59M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $186.72M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $131.99M 10-K · filed 2022-03-01 |
| 2020-09-30 | $175.83M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $158.56M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $169.16M 10-Q/A · filed 2020-05-26 |
| 2019-12-31 | $116.60M 10-K · filed 2021-03-01 |
| 2019-09-30 | $56.93M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $64.73M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $58.25M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $51.55M 10-K · filed 2020-03-09 |
| 2018-09-30 | $39.17M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $15.84M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $17.88M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $23.18M 10-K · filed 2019-03-06 |
| 2017-09-30 | $29.08M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $28.61M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $37.87M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $47.05M 10-K · filed 2018-03-07 |
| 2016-09-30 | $15.36M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $15.53M 10-Q · filed 2016-08-03 |
| 2015-06-30 | $9.35M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $9.46M 10-Q/A · filed 2015-08-13 |
| 2014-12-31 | $12.02M 10-K · filed 2016-03-08 |
| 2014-09-30 | $14.21M 10-Q · filed 2014-12-15 |
| 2013-12-31 | $11.33M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |